Second malignant neoplasia in early (TIS-T1) glottic carcinoma

Head Neck. 2006 Jun;28(6):501-7. doi: 10.1002/hed.20453.

Abstract

Background: We performed a population-based study to determine the incidence and patterns of second malignant neoplasia (SMN) in early glottic carcinoma.

Methods: All patients diagnosed with Tis-T1 glottic carcinoma in the southwest of the Netherlands between 1982 and 1993 (359) were included. Sources of the data were patient charts and the regional cancer registry.

Results: SMN incidence was 27.7% (median follow-up, 89 months). Observed-to-expected ratios were increased for lung, bladder, urinary tract, pancreatic, colorectal, and head and neck cancers. The incidence of head and neck and esophageal cancer was surprisingly low.

Conclusions: Patients with early glottic carcinoma are at a reliably increased risk of the development of tumors not only in the areas of the upper aerodigestive tract, but also in the bladder, pancreas, and colorectum. The low incidence of head and neck and esophageal tumors does not appear to support routine panendoscopy in this patient population.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell / epidemiology*
  • Carcinoma, Squamous Cell / etiology
  • Carcinoma, Squamous Cell / mortality
  • Digestive System Neoplasms / epidemiology
  • Digestive System Neoplasms / etiology
  • Digestive System Neoplasms / mortality
  • Female
  • Follow-Up Studies
  • Glottis
  • Head and Neck Neoplasms / epidemiology*
  • Head and Neck Neoplasms / etiology
  • Head and Neck Neoplasms / mortality
  • Humans
  • Incidence
  • Laryngeal Neoplasms / epidemiology*
  • Laryngeal Neoplasms / etiology
  • Laryngeal Neoplasms / mortality
  • Lung Neoplasms / epidemiology*
  • Lung Neoplasms / etiology
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / epidemiology*
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / mortality
  • Netherlands / epidemiology
  • Smoking / adverse effects
  • Survival Rate